This 2003 single-center, randomized, double-masked, placebo-controlled trial evaluated the efficacy of intravenous ceftriaxone in 55 patients with post-Lyme syndrome (PLS) experiencing severe fatigue persisting for at least six months post-treatment. Participants received either 28 days of IV ceftriaxone or placebo. The primary outcome was improvement in fatigue, assessed via an
